
Amphastar (AMPH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
170.5M
Gross Profit
85.3M
49.99%
Operating Income
37.3M
21.87%
Net Income
25.3M
14.83%
EPS (Diluted)
$0.51
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
875.0M
Shareholders Equity
751.3M
Debt to Equity
1.16
Cash Flow Metrics
Operating Cash Flow
16.2M
Free Cash Flow
24.4M
Revenue & Profitability Trend
Amphastar Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 732.0M | 644.4M | 499.0M | 437.8M | 349.8M |
Cost of Goods Sold | 358.1M | 293.3M | 250.1M | 238.0M | 206.5M |
Gross Profit | 373.9M | 351.1M | 248.9M | 199.7M | 143.3M |
Gross Margin % | 51.1% | 54.5% | 49.9% | 45.6% | 41.0% |
Operating Expenses | |||||
Research & Development | 73.9M | 73.7M | 74.8M | 60.9M | 67.2M |
Selling, General & Administrative | 94.5M | 80.4M | 66.6M | 68.9M | 65.2M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 168.4M | 154.1M | 141.4M | 129.9M | 132.4M |
Operating Income | 205.4M | 197.0M | 107.5M | 69.9M | 11.0M |
Operating Margin % | 28.1% | 30.6% | 21.5% | 16.0% | 3.1% |
Non-Operating Items | |||||
Interest Income | 10.6M | 5.5M | 1.3M | 601.0K | 642.0K |
Interest Expense | 30.3M | 27.2M | 1.8M | 885.0K | 374.0K |
Other Non-Operating Income | 4.1M | -3.9M | 9.1M | 14.5M | -6.6M |
Pre-tax Income | 189.8M | 171.4M | 116.0M | 84.1M | 4.6M |
Income Tax | 29.7M | 31.8M | 23.5M | 20.6M | 3.5M |
Effective Tax Rate % | 15.6% | 18.6% | 20.2% | 24.5% | 76.3% |
Net Income | 159.5M | 137.5M | 91.4M | 63.3M | 1.1M |
Net Margin % | 21.8% | 21.3% | 18.3% | 14.5% | 0.3% |
Key Metrics | |||||
EBITDA | 277.3M | 240.3M | 146.2M | 111.6M | 30.2M |
EPS (Basic) | $3.29 | $2.85 | $1.88 | $1.30 | $0.03 |
EPS (Diluted) | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 |
Basic Shares Outstanding | 48429000 | 48265000 | 48551000 | 47777000 | 47038000 |
Diluted Shares Outstanding | 48429000 | 48265000 | 48551000 | 47777000 | 47038000 |
Income Statement Trend
Amphastar Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 151.6M | 144.3M | 156.1M | 126.4M | 92.6M |
Short-term Investments | 70.0M | 112.5M | 19.7M | 10.3M | 13.0M |
Accounts Receivable | 136.3M | 114.9M | 88.8M | 78.8M | 66.0M |
Inventory | 153.7M | 105.8M | 103.6M | 92.8M | 96.8M |
Other Current Assets | 18.2M | 9.1M | 7.6M | 7.3M | 6.8M |
Total Current Assets | 534.1M | 489.6M | 378.3M | 318.1M | 279.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 47.3M | 32.9M | 26.3M | 27.2M | 20.7M |
Goodwill | 593.7M | 616.5M | 40.4M | 42.2M | 44.6M |
Intangible Assets | 587.6M | 610.1M | 34.2M | 35.6M | 36.7M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 97.1M | 79.2M | 59.4M | 39.1M | 30.2M |
Total Non-Current Assets | 1.0B | 1.0B | 363.7M | 353.4M | 351.6M |
Total Assets | 1.6B | 1.5B | 742.0M | 671.5M | 631.2M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 30.5M | 25.4M | 20.5M | 22.2M | 24.4M |
Short-term Debt | 7.0M | 4.3M | 6.0M | 5.2M | 15.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 173.8M | 225.4M | 94.9M | 103.8M | 112.2M |
Non-Current Liabilities | |||||
Long-term Debt | 643.5M | 619.3M | 96.5M | 99.5M | 51.6M |
Deferred Tax Liabilities | 7.0M | 6.1M | 7.4M | 7.1M | 5.4M |
Other Non-Current Liabilities | 20.9M | 22.7M | 14.6M | 15.7M | 13.2M |
Total Non-Current Liabilities | 671.4M | 648.1M | 118.5M | 122.2M | 70.3M |
Total Liabilities | 845.2M | 873.5M | 213.3M | 226.0M | 182.5M |
Equity | |||||
Common Stock | 6.0K | 6.0K | 6.0K | 6.0K | 5.0K |
Retained Earnings | 568.8M | 409.3M | 271.7M | 180.3M | 117.8M |
Treasury Stock | 332.7M | 247.4M | 189.5M | 150.5M | 121.8M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 732.3M | 639.4M | 528.7M | 445.5M | 448.7M |
Key Metrics | |||||
Total Debt | 650.5M | 623.6M | 102.6M | 104.7M | 67.3M |
Working Capital | 360.3M | 264.2M | 283.5M | 214.3M | 167.5M |
Balance Sheet Composition
Amphastar Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 159.5M | 137.5M | 91.4M | 63.3M | 1.1M |
Depreciation & Amortization | 57.2M | 41.8M | 28.3M | 26.5M | 25.2M |
Stock-Based Compensation | 24.4M | 20.2M | 17.9M | 18.7M | 20.5M |
Working Capital Changes | -3.8M | -21.5M | -30.3M | -4.9M | 10.7M |
Operating Cash Flow | 226.3M | 175.7M | 91.9M | 108.1M | 58.6M |
Investing Activities | |||||
Capital Expenditures | -41.0M | -38.2M | -23.6M | -27.5M | -33.9M |
Acquisitions | -129.0M | -506.4M | 0 | 0 | - |
Investment Purchases | -76.8M | -144.6M | -35.8M | -17.4M | -13.6M |
Investment Sales | 126.0M | 38.6M | 28.0M | 18.8M | 12.4M |
Investing Cash Flow | -124.9M | -649.1M | -32.8M | -28.7M | -36.4M |
Financing Activities | |||||
Share Repurchases | -85.5M | -58.1M | -39.9M | -28.9M | -24.4M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 18.4M | 845.0M | 0 | 70.0M | 6.3M |
Debt Repayment | -8.3M | -318.7M | -1.8M | -37.9M | -8.4M |
Financing Cash Flow | -76.1M | 443.1M | -42.1M | -54.1M | -25.4M |
Free Cash Flow | 172.3M | 145.3M | 65.1M | 70.5M | 23.4M |
Net Change in Cash | 25.3M | -30.3M | 17.0M | 25.3M | -3.3M |
Cash Flow Trend
Amphastar Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
7.72
Forward P/E
4.87
Price to Book
1.35
Price to Sales
1.37
PEG Ratio
4.87
Profitability Ratios
Profit Margin
19.38%
Operating Margin
21.87%
Return on Equity
19.90%
Return on Assets
7.60%
Financial Health
Current Ratio
2.95
Debt to Equity
86.86
Beta
0.76
Per Share Data
EPS (TTM)
$2.76
Book Value per Share
$15.76
Revenue per Share
$15.13
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
amph | 1.0B | 7.72 | 1.35 | 19.90% | 19.38% | 86.86 |
Zoetis | 67.7B | 27.31 | 14.58 | 52.09% | 27.12% | 145.63 |
Haleon Plc - ADR | 43.4B | 21.95 | 5.45 | 9.38% | 13.81% | 53.41 |
BioCryst | 1.8B | -19.41 | -4.15 | 18.68% | -6.41% | -1.97 |
BGM | 1.6B | 15.00 | 4.42 | -16.52% | -26.32% | 0.22 |
Ani Pharmaceuticals | 1.5B | 51.63 | 3.31 | -4.57% | -3.12% | 142.03 |
Financial data is updated regularly. All figures are in the company's reporting currency.